The latest price target for Crinetics Pharmaceuticals (NASDAQ:CRNX) was reported by Cantor Fitzgerald on September 16, 2024. The analyst firm set a price target for $90.00 expecting CRNX to rise to within 12 months (a possible 69.33% upside). 37 analyst firms have reported ratings in the last year.

The latest analyst rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) was provided by Cantor Fitzgerald, and Crinetics Pharmaceuticals reiterated their overweight rating.

There is no last upgrade for Crinetics Pharmaceuticals

There is no last downgrade for Crinetics Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crinetics Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crinetics Pharmaceuticals was filed on September 16, 2024 so you should expect the next rating to be made available sometime around September 16, 2025.

While ratings are subjective and will change, the latest Crinetics Pharmaceuticals (CRNX) rating was a reiterated with a price target of $90.00 to $90.00. The current price Crinetics Pharmaceuticals (CRNX) is trading at is $53.15, which is out of the analyst’s predicted range.